Bukwang Pharmaceutical

KSC:003000 · KR7003000007

PharmaceuticalsSmall

360

Medium confidence — indicative

Value39

Profit price8

EV / EBIT10

Price / Owner Earnings6

Cash yield34

Owner Earnings Yield66

Dividend Yield1

Sales & asset price52

Price/Sales29

EV / Gross Profit49

Price/Book77

Quality47

Returns on capital66

Return on Capital61

Cash Return on Capital67

Return on Equity71

Profit margins53

EBIT Margin58

Gross Profitability48

Cash backing33

Cash Conversion21

Accruals11

Owner Earnings Margin67

Growth64

Sales growth25

Profit growth71

Profit Growth65

Long-Term EPS Growth70

Owner Earnings Growth79

Reinvestment47

Price momentum91

Safety61

Debt load71

Debt serviceability65

Refinancing30

Debt Payback100

Liquidity37

Sentiment43

Analyst ratings—

Expectations trend—

Market mood45

Value Creation10/20creating some value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Bukwang Pharmaceutical clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

TypePublic Company

ExchangeKOSE

Employees9

Websitebukwang.co.kr

ISINKR7003000007

Last UpdateApr 2, 2026

Indices

KOSPI (South Korea)

Themes

DiabetesCardiovascularUrologyNutraceuticalDermatologyEndocrinologyGastroenterologyNeurologyCentral Nervous SystemOncologyAllergyManufacturingMedical Device

Description

Analysis

Middle-of-the-road

Bukwang Pharmaceutical Co., Ltd. sits in the middle of our grid: average quality, average price, no obvious signal in either direction. Worth noting: the cash the business generates has lagged behind what the income statement shows.

On valuation, the picture is expensive. The owner-earnings multiple stands at 34.6×; owner earnings: the cash an owner could take out each year.

Growth is solid; the safety picture is adequate. The company scores 10/20 on our value-creation score: creating some value.

Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

20232026

All-time high

Jan 2023

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Bukwang Pharmaceutical with its peers

Samsung Pharm

KSC:001360

—

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Kwangdong Pharmaceutical

KSC:009290

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Dong-A ST

KSC:170900

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Bora Pharmaceuticals

TAI:6472

CountryTaiwan

IndustryPharmaceuticals

SizeMedium

Full Stock Analysis →

JW Pharmaceutical

KSC:001060

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Reyon Pharmaceutical

KSC:102460

CountrySouth Korea

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →